Kim Monkhorst
YOU?
Author Swipe
View article: Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastases
Divergence of DNA tumor mutations in cerebrospinal fluid in metastatic breast cancer patients with leptomeningeal metastases Open
In 20 % of breast cancer patients with LM, genetic alterations in the CSF were discordant from the primary tumor and/or systemic metastases. These genetic alterations involved in particular the PTEN-PI3K-AKT pathway in TN breast cancer. No…
View article: Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study Open
Background Despite treatment with curative intent, many patients with localized non-small cell lung cancer (NSCLC) develop recurrence. The current challenge is to identify high-risk patients to guide adjuvant treatment. Identification of r…
View article: Supplementary Figure S5 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Figure S5 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Figure S5: Post-IIT ADC 0-50-800 relative to baseline of matched lymph nodes (baseline pathologic sampled tumor positive lymph nodes also sampled post-IIT, median 106% vs 144%, p=0.20). Abbreviations: ADC, apparent diffusion …
View article: Supplementary Table S3 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Table S3 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Table S3: Immune-related adverse events during the safety period. Numbers depict the number of patients experiencing the event. If a patient the same event multiple occasions, the patient is counted only once, under the highe…
View article: Supplementary Figure S3 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Figure S3 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Figure S3: Post-IIT TLG of matched lymph nodes (baseline pathologic sampled tumor positive lymph nodes also sampled post-IIT) (median 11.3 vs 0, p=0.04). Abbreviations: TLG, total lesion glycolysis; g, grams; path, pathology.
View article: Supplementary Table S6 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Table S6 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Table S6: Metabolic response evaluation.
View article: Supplementary Table S2 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Table S2 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Table S2: Representativeness of Study Participants
View article: External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma
External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma Open
Background Immune checkpoint inhibitors (ICIs) provide a significant survival benefit in non-small cell lung cancer (NSCLC) patients; however, accurately predicting which patients will benefit remains a challenge. As previously shown, the …
View article: Supplementary Figure S2 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Figure S2 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Figure S2: Baseline TLG of baseline pathologic sampled lymph nodes (median 19.4 vs 6.2, p=0.02). Abbreviations: TLG, total lesion glycolysis; g, grams; path, pathology.
View article: Data from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Data from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Purpose:The phase I induction trial (NCT04287894) assessed the feasibility and safety of induction immunotherapy (IIT) prior to concurrent chemoradiotherapy (cCRT) in patients with locally advanced non–small cell lung cancer (NSCLC).Patien…
View article: Supplementary Table S1 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Table S1 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Table S1: Histology, PD-L1 TPS and mutational analysis.
View article: Supplementary Figure S4 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Figure S4 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Figure S4: Post-IIT ADC relative to baseline of downstaged and not-downstaged patients (median 112% vs 113%, p=0.94). Abbreviation: ADC, apparent diffusion coefficient.
View article: Supplementary Table S5 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Table S5 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Table S5: All cause adverse events during the safety period. Numbers depict the number of patients experiencing the event. If a patient has the same event multiple occasions, the patient is counted only once, under the highes…
View article: Supplementary Table S4 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Table S4 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Table S4: Serious adverse events.
View article: Supplementary Figure S1 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Supplementary Figure S1 from Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Supplementary Figure S1: Sankey diagram of TNM stage at baseline and after IIT. Numbers depict number of patients per category.
View article: Clinical application of tumour whole genome sequencing in routine molecular diagnostics for solid cancer patients
Clinical application of tumour whole genome sequencing in routine molecular diagnostics for solid cancer patients Open
Molecular testing is increasingly relevant for enabling precision medicine for cancer patients. Whole genome sequencing (WGS) provides a tumour-agnostic solution for the growing complexity of DNA-based biomarker detection, with promising r…
View article: Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial Open
Purpose: The phase I induction trial (NCT04287894) assessed the feasibility and safety of induction immunotherapy (IIT) prior to concurrent chemoradiotherapy (cCRT) in patients with locally advanced non–small cell lung cancer (NSCLC). Pati…
View article: The DETECTION project part 1: An international Delphi survey about diagnostics and treatment of anterior mediastinal cystic lesions
The DETECTION project part 1: An international Delphi survey about diagnostics and treatment of anterior mediastinal cystic lesions Open
The survey outcomes showed heterogeneity in the diagnostics and indication for resection of anterior mediastinal cysts among thoracic medical experts. A large variation in radiological imaging, laboratory tests, surgery, pathological analy…
View article: Supplementary Table S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Table S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
STK11, KEAP1 and actionable EGFR alterations in the discovery cohort.
View article: Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure S2 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
The impact of tumor purity on the WGS-based TMB in the discovery cohort.
View article: Supplementary Table S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Table S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
Actionable EGFR alterations, TMB and DCB in the validation cohort.
View article: Supplementary Figure S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure S4 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
Alterations in STK11, KEAP1, or EGFR and survival of TMB-based subgroups in the validation cohort.
View article: Supplementary Figure S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
STK11/KEAP1/EGFR alterations and survival of TMB-based subgroups in the discovery cohort.
View article: Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Figure S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
The cTMB and outcome of ICB monotherapy in the discovery cohort.
View article: Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Table S3 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
Baseline characteristics of patients in the discovery cohort, stratified by the TMB and STK11/KEAP1/EGFR alteration status.
View article: Supplementary Table S5 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Table S5 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
Baseline characteristics of patients in the validation cohort, stratified by the TMB and STK11/KEAP1/EGFR alteration status.
View article: Supplementary Table S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Supplementary Table S1 from Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer Open
Clinicogenomic dataset of the discovery cohort used for biomarker analyses.